Table 1

Included cohorts with sample size and numbers of end point events

CohortCountryTotal number with two ultrasound scansNumber of subjects with diabetes without previous CVD eventsMean interval between the two ultrasound scans (years)Mean duration of clinical follow-up after the second ultrasound scan (years)Number of combined end point events among subjects with diabetesCrude event rate of the combined end point among subjects with diabetes (per 1,000 person-years)
AIR (25)Sweden297123.35.1116.2
ARIC (26)U.S.12,2211,1312.97.428133.5
BHS (27)U.S.554222.44.32*21.2*
Bruneck (28)Italy633475.08.01129.3
CAPS (22)Germany3,284743.15.2615.7
CCCC (29)Taiwan1,2851275.17.288.7
CHS1 (30)U.S.3,5518962.98.334846.9
CHS2 (30)U.S.297875.95.22555.5
CMCS (31)China920575.44.927.2
DIWA (20)Sweden418405.52.1223.4
EAS (32)U.K.620316.55.2425.0
EPICARDIAN (33)Spain16173.06.6121.5
EVA (34)France922572.013.219*25.3*
INVADE (35)Germany2,5344882.23.97036.6
KIHD (36)Finland891294.111.51854.1
NOMAS/INVEST (37)U.S.6471163.62.9514.8
PIVUS (38)Sweden680535.11.84*40.8*
PLIC (39)Italy1,538712.34.013.5
Rotterdam (40)The Netherlands2,6101586.45.45159.5
SAPHIR (41)Austria1,154354.69.513.0
SHIP (42)Germany1,7512835.25.55032.0
Tromsø (43)Norway4,003816.36.42548.1
  • *Number of deaths among subjects with diabetes. AIR, Atherosclerosis and Insulin Resistance study; ARIC, Atherosclerosis Risk In Communities study; BHS, Bogalusa Heart Study; Bruneck, Bruneck study; CAPS, Carotid Atherosclerosis Progression Study; CCCC, Chin-Shan Community Cardiovascular Cohort; CMCS, Chinese Multi-provincial Cohort Study; DIWA, Diabetes, Impaired glucose tolerance in Women and Atherosclerosis; EAS, Edinburgh Artery Study; EPICARDIAN, Estudio epidemiológico sobre enfermedades y factores de riesgo cardiovasculares en ancianos españoles; KIHD, Kuopio Ischaemic Heart Disease study; PIVUS, Prospective Investigation of the Vasculature in Uppsala Seniors; PLIC, Progression of Lesions in the Intima of the Carotid; Rotterdam, Rotterdam Study; SAPHIR, Salzburg Atherosclerosis Prevention program in subjects at High Individual Risk; Tromsø, Tromsø Study.